BiotechTube
Home/Pipeline/In-house Discovery Program

In-house Discovery Program

Autoimmune Diseases

DiscoveryActive

Key Facts

Indication
Autoimmune Diseases
Phase
Discovery
Status
Active
Company
Enhanced Genomics

About Enhanced Genomics

Enhanced Genomics is a private, pre-revenue biotechnology company leveraging a proprietary 3D multi-omics platform, GenLink™, to decode the genetic drivers of disease and identify novel therapeutic targets. Spun out from pioneering research at the Babraham Institute, the company operates both an in-house discovery program focused on autoimmune diseases and selectively partners with other biopharma entities. Its core value proposition is a 10x faster target identification process and a claimed 2x increase in drug development success through genetic validation.

View full company profile

Therapeutic Areas

Autoimmune

Other Autoimmune Diseases Drugs

DrugCompanyPhase
Humira (Adalimumab) BiosimilarNeuCloneEarly Preclinical
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelastellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial